Trending Now
Precision BioSciences (NASDAQ:DTIL) Enters Oncology Development Partnership With SpringWorks (NASDAQ:SWTX) And...
Precision BioSciences (NASDAQ:DTIL) has announced that it has entered a clinical trial partnership agreement with SpringWorks Therapeutics Inc. (NASDAQ:SWTX) to evaluate PBCAR269A in combination...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Cytokinetics Incorporated (NASDAQ:CYTK) Commences Phase 1 Clinical Trial of CK-271 In...
Cytokinetics Incorporated (NASDAQ:CYTK) has announced the dosing of the first subjects in Phase 1 single-ascending doses, placebo-controlled CK-3772271 (CK-271) clinical study. CK-271 is the...
MAKE IT MODERN
LATEST REVIEWS
Charlotte’s Web Holdings Inc (OTCMKTS:CWBHF) Gets Back on the Map with...
Charlotte's Web Holdings Inc (OTCMKTS:CWBHF) is a leader in the CBD space based on market penetration over recent years.
MAKE IT MODERN
PERFORMANCE TRAINING
Immix Biopharma Inc. (NASDAQ: IMMX) Release Study Showing That IMX-110 Can Create 50% Response...
Immix Biopharma Inc. (NASDAQ: IMMX) has announced study findings demonstrating that its flagship candidate IMX-110 created a 50% response rate in first-line-treatment-resistant cancer- soft...
BiondVAX Pharmaceuticals Ltd. (NASDAQ: BVXV) Enters Definitive Agreements To Develop And Commercialize novel COVID-19...
BiondVAX Pharmaceuticals Ltd. (NASDAQ: BVXV) has signed definitive agreements with Max Planck Institute of Biophysical Chemistry's parent organization, Max Planck Society, and University Medical...
CytomX Therapeutics Inc. (NASDAQ: CTMX) Reports Interim Results For Phase 2 Study HNSCC and...
CytomX Therapeutics Inc. (NASDAQ: CTMX) has announced interim results of the second phase study in patients with head and neck squamous cell carcinoma and...
Citius Pharmaceuticals Inc. (NASDAQ:CTXR) Expands Its Intellectual Property Associated With Mino-Wrap To Enhance Its...
Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is pursuing a new standard of care thanks to the growing markets and demand for advanced cancer drugs. The company...
Assembly Biosciences Inc. (NASDAQ: ASMB) Discontinues ABI-H2158 Development Following Elevated ALT Levels
Assembly Biosciences Inc. (NASDAQ: ASMB) has announced that it will discontinue ABI-H2158 (2158) development t after observing elevated ALT levels consistent with treatment-induced hepatoxicity...
MAKE IT MODERN
